We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+3.35%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$957M
AUM Growth
+$1.08M
Cap. Flow
-$9.87M
Cap. Flow %
-1.03%
Top 10 Hldgs %
32.99%
Holding
140
New
9
Increased
34
Reduced
55
Closed
6

Top Buys

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$11.5M
2
SUPN icon
Supernus Pharmaceuticals
SUPN
+$9.5M
3
ONC
BeOne Medicines Ltd
ONC
+$9.49M
4
INCY icon
Incyte
INCY
+$8.91M
5
CELG
Celgene Corp
CELG
+$8.11M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$20.7M
2
GILD icon
Gilead Sciences
GILD
+$16.8M
3
ABMD
Abiomed Inc
ABMD
+$10.8M
4
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$8.6M
5
ABBV icon
AbbVie
ABBV
+$7.85M

Sector Composition

Rank Sector Weight
1 Healthcare 95.72%
2 Financials 0.41%
3 Industrials 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
26
Gilead Sciences
GILD
$167B
$13M 1.36%
181,100
-221,441
-55% -$16.8M
IONS icon
27
Ionis Pharmaceuticals
IONS
$8.99B
$12.9M 1.35%
256,706
-9,000
-3% -$494K
TEVA icon
28
Teva Pharmaceuticals
TEVA
$37.3B
$12.7M 1.33%
671,940
+90,000
+15% +$1.35M
WMGI
29
DELISTED
Wright Medical Group Inc
WMGI
$12M 1.26%
541,801
– –
BDX icon
30
Becton Dickinson
BDX
$43.6B
$11.8M 1.23%
56,375
– –
LIVN icon
31
LivaNova
LIVN
$4.43B
$11.8M 1.23%
147,269
-10,800
-7% -$857K
CI icon
32
Cigna
CI
$74.5B
$11.7M 1.22%
57,650
+10,000
+21% +$1.99M
CNC icon
33
Centene
CNC
$32.8B
$11.6M 1.22%
230,780
-7,080
-3% -$343K
HZNP
34
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$11.6M 1.21%
794,062
+307,599
+63% +$4.32M
MGNX icon
35
MacroGenics
MGNX
$285M
$10.7M 1.12%
564,401
+131,102
+30% +$2.45M
REGN icon
36
Regeneron Pharmaceuticals
REGN
$70.9B
$10.5M 1.09%
27,800
-2,400
-8% -$972K
ONC
37
BeOne Medicines Ltd
ONC
$32.4B
$10.1M 1.06%
+103,650
New +$9.49M
ZBH icon
38
Zimmer Biomet
ZBH
$17.6B
$10M 1.05%
85,490
-10,300
-11% -$1.16M
VTRS icon
39
Viatris
VTRS
$20.1B
$10M 1.04%
236,300
+55,100
+30% +$2.11M
SUPN icon
40
Supernus Pharmaceuticals
SUPN
$2.79B
$9.58M 1%
+240,400
New +$9.5M
THC icon
41
Tenet Healthcare
THC
$16.8B
$9.34M 0.98%
616,796
– –
LH icon
42
Labcorp
LH
$23.2B
$9.06M 0.95%
66,138
+2,490
+4% +$329K
SHPG
43
DELISTED
Shire pic
SHPG
$8.75M 0.91%
56,435
+13,995
+33% +$2.07M
IART icon
44
Integra LifeSciences
IART
$1.5B
$8.72M 0.91%
182,200
+5,350
+3% +$262K
HUM icon
45
Humana
HUM
$48B
$8.27M 0.86%
33,350
+2,000
+6% +$494K
TSRO
46
DELISTED
TESARO, Inc.
TSRO
$5.97M 0.62%
72,100
+61,100
+555% +$5.99M
HCM icon
47
HUTCHMED
HCM
$1.86B
$5.26M 0.55%
133,850
+69,277
+107% +$2.21M
ABMD
48
DELISTED
Abiomed Inc
ABMD
$5.06M 0.53%
27,000
-58,110
-68% -$10.8M
TMO icon
49
Thermo Fisher Scientific
TMO
$198B
$4.9M 0.51%
25,808
– –
COO icon
50
Cooper Companies
COO
$14B
$4.86M 0.51%
89,200
-6,800
-7% -$398K
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2017 Portfolio in Review

As of Q4 2017, Bellevue Group held 140 positions worth $957M, up 0.11% from $956M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Bellevue Group's Q4 2017 filing shows 9 new, 34 increased, 55 reduced and 6 closed positions. Its largest new stake was Supernus Pharmaceuticals: 240,400 shares worth $9.58M. The largest sale was Amgen, an estimated $20.7M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Financials and Industrials.

  • Bellevue Group's largest Q4 2017 buy was Supernus Pharmaceuticals: 240,400 shares worth $9.58M.
  • Bellevue Group added most to DexCom in Q4 2017, an estimated $11.5M increase.
  • Bellevue Group's biggest Q4 2017 reduction was Amgen, cutting an estimated $20.7M.
  • Bellevue Group fully exited MALLINCKRODT PUBLIC LIMITED COMPANY in Q4 2017, selling an estimated $8.6M.
  • Bellevue Group's ten largest holdings make up 33% of its $957M portfolio in Q4 2017.
  • Bellevue Group opened 9 new positions and closed 6 in Q4 2017.
  • Bellevue Group's portfolio value rose 0.11% quarter-over-quarter to $957M.

Based on Bellevue Group's 13F filing for Q4 2017, filed 14 Feb 2018.